Is the FDA biased?

25 July 2018

By Dr Nicola Davies

When the US Food and Drug Administration was formed, its main purpose was to protect consumers from harmful medications that had no prior regulation. While this purpose is certainly in the public interest, the FDA, like many governmental agencies, has become a massive bureaucracy subject to influence from all sides, says Dr Nicola Davies in her monthly blog for The Pharma Letter.

From the presence of industry professionals on advisory committees to the fees they pay to have new drugs reviewed, how much bias is there within the FDA? If there is bias, how can the FDA ensure it continues to put the needs of the patient first?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK